H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (NASDAQ:SPRO) Inc on Monday, setting a price target of $28, which is approximately 137.69% above the present share price of $11.78.
Selvaraju expects Spero Therapeutics Inc to post earnings per share (EPS) of -$1.32 for the second quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Spero Therapeutics, with an average price target of $22.
The analysts price targets range from a high of $25 to a low of $20.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $3.63 million and a net profit of -$25.88 million. The company's market cap is $239.47 million.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is a 5-star analyst with an average return of 22.1% and a 55.8% success rate.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
